Sarina Piha-Paul

Jul 30, 2024 | nature.com | Sarina Piha-Paul |Vivek Subbiah |Aung Naing |Jaffer Ajani |Kanwal Raghav |Gordon Mills | +3 more

AbstractCancer cells with BRCA1/2 deficiencies are sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. We evaluated the efficacy of talazoparib in DNA-Damage Repair (DDR)-altered patients. In this phase II trial, patients were enrolled onto one of four cohorts based on molecular alterations: (1) somatic BRCA1/2, (2) other homologous recombination repair pathway, (3) PTEN and (4) germline BRCA1/2.